Skip to content

Efficacy and Safety of the Soricle for Subjective Tinnitus Relief

Efficacy and Safety of the Soricle, a Class III Combination Device of Vagus Nerve Stimulation and Sound Stimulation, for Subjective Tinnitus Relief: A Prospective, Single-Center, Randomized, Double-Blind, Sham-Controlled, Exploratory Clinical Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07548320
Enrollment
36
Registered
2026-04-23
Start date
2025-03-10
Completion date
2025-09-08
Last updated
2026-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subjective Tinnitus, Tinnitus

Keywords

tinnitus, vagus nerve stimulation, sound stimulation, auricular stimulation, medical device

Brief summary

This study was conducted to evaluate the efficacy and safety of Soricle, a medical device combining transcutaneous vagus nerve stimulation and sound stimulation, in patients with subjective tinnitus. Participants were randomly assigned to either the active treatment group or a sham control group in a double-blind manner. The device was used daily for 8 weeks. The primary objective was to assess the improvement in tinnitus symptoms, and safety was evaluated throughout the study period.

Detailed description

This was a prospective, single-center, randomized, double-blind, sham-controlled exploratory clinical trial designed to evaluate the efficacy and safety of Soricle, a Class III medical device combining transcutaneous vagus nerve stimulation (tVNS) and sound stimulation, for the treatment of subjective tinnitus. Participants diagnosed with subjective tinnitus were randomly assigned in a 1:1 ratio to either the active treatment group or the sham control group. The investigational device was applied daily for 8 weeks. The primary objective of the study was to evaluate the improvement in tinnitus symptoms, and secondary objectives included additional efficacy assessments and safety evaluations. Safety was monitored throughout the study, including the assessment of adverse events. The study was conducted in accordance with ICH-GCP guidelines and was approved by the Institutional Review Board. All participants provided written informed consent prior to participation.

Interventions

DEVICESham Device

A sham device identical in appearance to the active device but without delivering therapeutic stimulation.

DEVICEtVNS Device

A medical device delivering transcutaneous vagus nerve stimulation (tVNS) via auricular stimulation.

DEVICEtVNS + Sound Stimulation Device

A medical device delivering combined transcutaneous vagus nerve stimulation (tVNS) and sound stimulation.

Sponsors

Neurive Co.,Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

This study was conducted in a double-blind manner. Participants, investigators, care providers, and outcome assessors were blinded to group assignments. The active device and sham device were identical in appearance to maintain blinding.

Intervention model description

Participants were randomized in a 1:1 ratio to either the active treatment group or the sham control group in a parallel design.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults aged 18 years or older * Patients with subjective tinnitus * Able to understand and provide informed consent * Willing to comply with study procedures

Exclusion criteria

* Objective tinnitus * Severe hearing loss requiring immediate treatment * History of neurological or psychiatric disorders that may affect study outcomes * Use of other tinnitus treatments during the study period * Any condition that, in the investigator's judgment, may interfere with study participation

Design outcomes

Primary

MeasureTime frameDescription
Change in Tinnitus Handicap Inventory (THI) Score8 weeksThe change in Tinnitus Handicap Inventory (THI) score from baseline to 8 weeks was assessed to evaluate the effectiveness of the intervention.

Countries

South Korea

Contacts

PRINCIPAL_INVESTIGATORJaegu Cho

Korea University Guro Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 24, 2026